Significance and pathogenesis of septic shock

Current Topics in Microbiology and Immunology

Volumn 216, Issue , 1996, Pages 14-37

  Brandtzaeg, P ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; BETA ENDORPHIN; BINDING PROTEIN; COMPLEMENT; CYTOKINE; ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; EXOTOXIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; KININ; LIPID A; LIPOTROPIN; PEPTIDOGLYCAN; PHOSPHOLIPASE A2; TEICHOIC ACID; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

BACTERIAL CELL WALL; BLOOD CLOTTING; COMPLEMENT ACTIVATION; FIBRINOLYSIS; GRAM POSITIVE BACTERIUM; HEART MUSCLE; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

ANIMALS; BLOOD COAGULATION; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; LIPOPOLYSACCHARIDES; SHOCK, SEPTIC;

EID: 0030324466     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80186-0_2     Document Type: Article

References (137)

1. Andersen BM, Solberg O, Bryn K, Fröholm LO, Gaustad P, Hølby EA, Kristiansen BE, Bøvre K (1987) Endotoxin liberation from Neisseria meningitidis isolated from carriers and clinical cases. Scand J Infect Dis 19: 409-419
2. Behre G, Schedel I, Nentwig B, Wörmann B, Essink M, Hiddemann W (1992) Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of antiendotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins. Antimicrob Agents Chemother 36: 2139-2146
3. 32-labelled Escherichia coli and staphylococci by the reticuloendothelial system. J Exp Med 110: 27-48
4. Bone R, Said S, Hiller C, Wilson F (1980) Vasoactive intestinal polypeptide in endotoxin shock. Am Rev Respir Dis 121: 113
5. Bone RC (1991) The pathogenesis of sepsis. Ann Intern Med 115 457-469
6. Bone RC (1993) Gram-negative sepsis: a dilemma of modern medicine Clin Microbiol Rev 6: 57-68
7. Brandtzaeg P (1995) Pathogenesis of meningococcal infections. In: Cartwrit K (ed) Meningococcal disease. Wiley, Chichester, pp 71-114
8. Brandtzaeg P, Kierulf P (1992) Endotoxin and meningococcemia. Intravascular inflammation induced by native endotoxin in man. In: Ryan JL, Morrison DC (eds) Immunopharmacology and pathophysiology. CRC Press, Boca Raton, pp 327-346 (Bacterial endotoxic eipopolysaccharides, vol 2)
9. Brandtzaeg P, Kierulf P (1992) Endotoxin and meningococcemia. Intravascular inflammation induced by native endotoxin in man. In: Ryan JL, Morrison DC (eds) Immunopharmacology and pathophysiology. CRC Press, Boca Raton, pp 327-346 (Bacterial endotoxic eipopolysaccharides, vol 2)
10. Brandtzaeg P, Kierulf P, Gaustad P, Skulberg A, Bruun JN, Halvorsen S, Sørensen E (1989a) Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 159 195-204
11. Brandtzaeg P, Mollnes TE, Kierulf P (1989b) Complement activation and endotoxin levels in systemic meningococcal disease. J Infect Dis 160: 58-65
12. Brandtzaeg P, Øktedalen O, Kierulf P, Opstad PK (1989c) Elevated VIP and plasma endotoxin in human gram-negative septic shock. Regul Pept 24: 37-44
13. Brandtzaeg P, Sandset M, Joø GB, Øvstebø R, Kierulf P, Abildgaard U (1989d) The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb Res 55: 459-470
14. Brandtzaeg P, Joø GB, Brusletto B, Kierulf P (1990) Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromb Res 57: 271-278
15. Brandtzaeg P, Bryn K, Kierulf P, Øvstebø R, Namork E, Aase B, Jantzen E (1992) Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 89: 816-823
16. Brandtzaeg P, Øvstebø R, Kierulf P (1995) Bacteremia and compartmentalization of LPS in meningococcal disease. In: Levin J, Alving CR, Munford R, Redl H (eds) Lipopolysaccharides from genes to therapy. Wiley, New York pp 219-233
17. Brandtzaeg P, Osnes L, Øvstebø R, Joø GB, Westvik ÅB, Kierulf P (1996a) Net inflammatory capacity of human septic shock plasma evaluated by a monocyte based target cell assay. J Exp Med (in press)
18. Brandtzaeg P, Høgåsen K, Kierulf P, Mollnes TE (1996b) The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 173: 647-655
19. Brazilian Purpuric Fever study Group (1987) Epidemic purpura fulminans associated with antecedent purulent conjunctivitis. Lancet 2: 757-763
20. Burrell R (1994) Human responses to bacterial endotoxin. Circ Shock 43: 137-153
21. Calandra T, Baumgartner JD, Grau GE, Wu MM, Lambert PH, Schellekens J, Verhoef J, Glauser MP, and the Swiss-Dutch J5 Immunoglobulin Study Group (1990) Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 161: 982-987
22. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, and the Swiss-Dutch J5 Immunoglobulin Study Group (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 91: 23-29
23. Cannon JC, Tompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JWM, Enders S, Lonnemann G, Corsetti J, Chernow B, Wilmore DW (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161: 79-84
24. Casale TB, Ballas ZK, Kaliner MA, Keahey TM (1990) The effect of intravenous endotoxin on various host-effector molecules. J Allergy Clin Immunol 85: 45-51
25. Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119: 771-778
26. Cavaillon JM, Pitton C, Fitting C (1994) Endotoxin tolerance is not a LPS-specific phenomenon: partial mimicry with IL-1, IL-10 and TGFβ J Endotoxin Res 1: 21-29
27. Cherry C, Schwab JH (1987) Endotoxin-like products of grampositive bacteria In: Rietschel ET (ed) Chemistry of endotoxin. Elsevier Amstrdam, pp 376-410 (Handbook of endotoxin, vol 1)
28. Cherry C, Schwab JH (1987) Endotoxin-like products of grampositive bacteria In: Rietschel ET (ed) Chemistry of endotoxin. Elsevier Amstrdam, pp 376-410 (Handbook of endotoxin, vol 1)
29. Cochrane CG (1985) The contact activation system in septic shock In. Hinshaw LB (ed) Pathophysiology of endotoxin Elsevier, Amsterdam, pp 286-298 (Handbook of endotoxin, vol 2)
30. Cochrane CG (1985) The contact activation system in septic shock In. Hinshaw LB (ed) Pathophysiology of endotoxin Elsevier, Amsterdam, pp 286-298 (Handbook of endotoxin, vol 2)
31. Creasey AA, Chang ACK, Feigen L, Wün TC, Taylor FB, Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock J Clin Invest 91: 2850-2860
32. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parillo JE (1986) The coronary circulation in human septic shock Circulation 73: 637-644
33. Da Silva AMT, Kaulbach HC, Chuidian FC, Lambert DR, Suffredini AF, Danner RL (1993) Shock and multiple organ dysfunction after self administration of Salmonella endotoxin. N Engl J Med 328: 1457-1460
34. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17: 975-978
35. Danner RL, Elin RL, Husseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock Chest 99. 169-175
36. De Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJM, Hack CE, Taylor FB (1993) Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a bifasic activation pattern. Infect Immun 61: 4293-4301
37. De Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262: 249-251
38. Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 17: 489-494
39. DeLa Cadena RA, Suffredini AF, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW (1993) Activation of the kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 81: 3313-3317.
40. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S (1995) High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 171: 229-232
41. DeVoe IW, Gilchrist JE (1973) Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 138. 1156-1167
42. Dhainaut JF, Huyghebaert MF, Monsallier JF et al. (1987) Coronary hemodynamics and myocardial metabolism of lactate, free fatty acid, glucose, and ketones in patients with septic shock. Circulation 75: 533-541
43. Drake TA, Cheng J, Chang A, Taylor FB (1993) Expression of tissue factor, thrombomodulm, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142: 1458-1470
44. Dziarski R (1993) The 70 kDa peptidoglycan/lipopolysaccharide receptor In: Levin J, Alving CR, Munford RS, Stütz PL (eds) Bacterial endotoxin recognition and effector mechanisms. Elsevier, Amsterdam, pp 151-165
45. Elin RJ, Wolff SM, McAdam KPWJ, Chedid L, Audibert F, Bernard C, Oberling F (1981) Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis 144: 329-336
46. Engebretsen LF, Kierulf P, Brandtzaeg P (1986) Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Tromb Res 42: 713-716
47. Fischer E, van Zee KJ, Marano MA, Rock CS, Kenny JS, Poutsiaka DD, Dinarello CA, Lowry SF, Moldawer LL (1992) Interleukin-1-receptor antagonist circulates in experimental inflammation and in human disease Blood 79: 2196-2200
48. Flegel WA, Wolpl A, Mannel DN, Northoff N (1989) Inhibition of endotoxin-induced activation of human nnonocytes by human lipoproteins. Infect Immun 57: 2237-2245
49. 2-INF/IL-6 in man. J Immunol 142: 2321-2324
50. Fong Y, Marano MA, Moldawer LL, Galvano SE, Kenny JS, Allison AC, Cerami A, Shires GT, Lowry SF (1990) The acute splancnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85. 1896-1904
51. Foreman NK, Wng WC, Cullen EJ, Stidham GL, Pearson TA, Shenep JL (1991) Endotoxic shock after transfusion of contaminated red blood cells in a child with sickle cell disease Pediatr Infect Dis J 10 624-626
52. Frank MM, Fries LF (1988) The role of complement in defence against bacterial disease. Clin Immunol Allergy 2: 335-361
53. Freund H, Ebeid AM, Fischer JE (1981) An increase in vasoactive intestinal peptide levels in canine endotoxin shock. Surg Gynecol Obstet 152: 604-606
54. Furie B, Furie BC (1992) Molecular and cellular biology of blood coagulation. N Engl J Med 326: 800-806
55. Girardin E, Gray GE, Dayer JM, Roux-Lombard P, the J5 Study Group, Lambert PH (1988) Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 319: 397-400
56. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: pathogenesis. Lancet 338: 732-739
57. Glauser MP, Heumann D, Baumgartner JD, Cohen J (1994) Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 18: S205-S216
58. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA (1991) Production of interieukin-1-receptor antagonist during experimental endotoxinaemia. Lancet 228. 1423-1424
59. Granowitz EV, Porat R, Mier JW, Orencole SF, Kaplanski G, Lynch EA, Ye K, Vannier E, Wolff SM, Dinarello CA (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans J Immunol 151: 1637-1645
60. Guidet B, Barakett V, Vassal T, Petit JC, Offenstadt G (1994) Endotoxemia and bacteremia in patients with sepsis syndrome in the intensive care unit. Chest 106 1194-1201
61. Gurll HJ, Reynolds DG, Holaday JW (1988) Evidence for a role of endorphins in the cardiovascular pathophysiology of primate shock. Crit Care Med 16: 521-530
62. Hack CE, Nuijens JH, Felt-Bersma RJF, Schreuder WO, Eerenberg-Belmer AJM, Paardekooper J, Bronsveld W, Thijs LG (1989) Elevated plasma levels of anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis JAMA 86: 20-26
63. Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A (1993) Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease 167: 471-475
64. Hangen DH, Stevens JH, Satoh PS, Hall EW, O'Hanley PT, Raffin T (1989) Complement levels in septic primates treated with anti-C5a antibodies. J Surg Res 46: 195-199
65. Hicklin H, Verghese A, Alvarez S (1987) Dysgonic fermenter 2 septicemia Rev Infect Dis 9: 884-890
66. Høsgäsen K, Mollnes TE, Brandtzaeg P (1994) Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal complement complex and vitronectin-thrombin-antithrombin complex. Infect Immun 62: 4874-4880
67. Hurley JC (1992) Antibiotic-induced release of endotoxin a reappraisal. Clin infect Dis 15: 840-854
68. Jafari HS, McCracken GH (1992) Sepsis and septic shock: a review for clinicians. Pediatr Infect Dis J 11: 739-749
69. Kierulf P, Andersen ÅBW (1990) Lipopolysaccharide-instructed, cryopreserved, human monocytes sequentially convert plasma fibrinogen to fibrin and lyse the fibrin formed. Pathobiology 59: 197-199
70. Kuhns DB, Alvord WG, Gallin JI (1995) Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans J Infect Dis 171: 145-152
71. Levi M, ten Cate H, van der Poll T, van Deventer SJH (1993) Pathogenesis of disseminated intravascular coagulation in sepsis JAMA 270: 975-979
72. Levin J, Poore TE, Zauber NP, Oser RS (1970) Detection of endotoxin in the blood of patients with sepsis due to gram-negative bacteria. N Engl J Med 283: 1313-1316
73. Levin J, Poore TE, Young NS, Margolis S, Zauber NP, Townes AS, Bell WR (1972) Gram-negative sepsis: detection of endotoxemia with the Limulus test. Ann Intern Med 76. 1-7
74. Lin RY, Astiz ME, Saxon JC, Saha DC, Rackow EC (1993) Alterations in C3, C4, factor B, and related metabolites in septic shock. Clin Immunol Immunopathol 69: 136-142
75. Lynn WA, Cohen J (1995) Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis 20: 143-158
76. Marchant A, Devière J, Byl B, De Groote D, Vincent JL, Goldman M (1994) Interleukin-10 production during septicaemia. Lancet 343: 707-708
77. Martich GD, Danner RL, Ceska M, Suffredini AF (1991) Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 173: 1021-1024
78. Martich GD, Boujoukos AJ, Suffredini AF (1993) Response of man to endotoxin. Immunobiology 187: 403-416
79. Marty C, Misset B, Tamion F, Fitting C, Carlet J, Cavaillon JM (1994) Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and non septic origin Crit Care Med 22: 673-679
80. McCabe WR (1973) Serum complement levels in bacteremias due to gram-negative organisms. N Engl J Med 288 21-23
81. McCartney AC, Banks JG, Clements GB, Sleigh JD, Tehrani M, Ledingham IM (1983) Endotoxaemia in septic shock, clinical and post mortem correlations Intensive Care Med 9 117-122
82. Mercier JC, Beaufils F, Hartmann JF, Azéma D (1988) Hemodynamic patterns of meningococcal shock in children. Crit Care Med 16: 27-33
83. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SH, Wilmore DW (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481-1486
84. Monnoz C, Misset, B, Fitting C, Blériot JP, Cavailion JM (1991) Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 21: 2177-2184
85. Moore FC, Moss NA, Revhaug A, Wilmore D, Mannick JA, Rodrick ML (1987) A single dose of endotoxin activates neutrophils without activating complement Surgery 102: 200-205
86. Morrison DC (1990) Diversity of mammalian macromolecules which bind to bacterial lipopolysaccharides. In: Nowotny A, Spitser JJ, Ziegler EJ (eds) Cellular and molecular aspects of endotoxin reactions. Elseviers, Amsterdam, pp 183-189
87. Morrison DC, Ryan JL (1987) Endotoxins and disease mechanisms Annu Rev Med 38. 417-432
88. Napolitano L, Chernow B (1988) Endorphins in circulatory shock Crit Care Med 16: 566-567
89. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL (1994) Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120: 771-783
90. Nies AS, Forsyth RP, Williams HE, Melmon KL (1968) Contribution of kinins to endotoxin shock in unanathetizied rhesus monkeys. Circ Res 22: 155-164
91. Offner F, Vogelaers JPD, Colardyn F, Baele G, Baudrihaye M, Vermeulen A, Leroux-Roels G (1990) Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 116. 100-105
92. Østerud B, Flaegstad T (1983) Increased tissue tromboplastin activity in monocytes of patients with meningococcal infection: related to unfavourable prognosis. Thromb Haemostas 49: 5-7
93. Parillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477
94. Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP (1990) Septic shock in humans Ann Intern Med 113: 227-242
95. Petrak RA, Balk RA, Bone RC (1989) Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthesis inhibitors in the pathogenesis of multiple organ failure. Crit Care Clin 5: 303-314
96. Pinsky MR, Vincent JL, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock Chest 103: 565-575
97. Pixley RA, DeLa Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB, Colman RW (1993) The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. J Clin Invest 91: 61-68
98. Pixley RA, Zellis S, Bankes P, DeLa Cadena PA, Page JD, Scott CF, Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW (1995) Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome Crit Care Med 23 41-51
99. Proud D, Kaplan AP (1988) Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol 6: 49-83
100. 2 - a mediator between proximal and distal effectors of inflammation Immunol Today 12: 143-146
101. 2 activity by intravenous infusion of endotoxin in patients with neoplassa. J Immunother 12: 242-246
102. Revhaug A, Lugren I, Jenssen TG, Giercksky KE, Burhol PG (1988) Vasoactive intestinal peptide in sepsis and shock Ann N Y Acad Sci 527. 536-545
103. Rietschel ET, Seydel U, Zähringer U, Schade UF, Brade L, Loppnow H, Feist W, Wang MH, Ulmer AJ, Flad HD, Brandenburg K, Kirikae T, Grimmecke D, Holst O, Brade H (1991) Bacterial endotoxin: molecular relationship between structure and activity. Infect Dis Clin North Am 5: 753-779
104. Shands JW, McKinney C (1989) Plasma endotoxin increased levels in neutropenic patients do not correlate with fever. J Infect Dis 159: 777-780
105. Spinas GA, Bloesch D, Kaufmann MT, Keller U, Dayer JM (1990) Induction of plasma inhibitors of interieukin 1 and TNF-α activity by endotoxin administration to normal humans. Am J Physiol 259: R993-R997
106. Spinas GA, Keller U, Brockhaus M (1992) Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 90: 533-536
107. Spitznagel JK (1990) Antibiotic proteins of human neutrophils. J Clin Invest 86: 1381-1386
108. Sprung CL, Schultz DR, Marcial E, Caralis PV, Gelbard MA, Arnold PI, Long WM (1986) Complement activation in septic shock patients. Crit Care Med 14: 525-528
109. Suffredini AF, Harpel PC, Parrillo JE (1989a) Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320: 1165-1172
110. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE (1989b) The cardiovascular response of humans to the administration of endotoxin. N Engl J Med 321: 280-287
111. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parrillo JE (1992) Pulmonary and oxygen transport effects on intravenously administered endotoxin in normal humans. Am Rev Respir Dis 145: 1398-1403
112. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925
113. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE (1988) Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 26: 227-235
114. Taylor FB, Chang A, Ruf W, Morrisey JH, Hinshaw L, Catlett R, Blick K, Edgington TS (1991) Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33. 127-135
115. Tracey KJ, Fong Y, Hesse Dg, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662-664
116. 2 levels with circulatory collapse. Crit Care Med 16: 1-7
117. Van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJH, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW (1990) Activation of the coagulation after administration of tumor necrosis factor to nornal subjects. N Engl J Med 322: 1622-1627
118. Van der Poll T, Romijn JA, Endert E, Borm JJJ, Büller HR, Sauerwein HP (1991 a) Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans Am J Physiol 261: E457-E465
119. Van der Poll T, Levi M, Büller HR, van Deventer SJH, de Boer JP, Hack CE, ten Cate JW (1991b) Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 174: 729-732
120. Van der Poll T, van Deventer SJH, Büller HR, Sturk A, ten Cate JW (1991c) Comparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. J Infect Dis 164: 599-601
121. Van der Poll T, van Deventer SJH, Hack CE, Wolbink GJ, Aarden LA, Büller HR, ten Cate JW (1992) Effects on leukocytes following injection of tumor necrosis factor into healthy humans. Blood 79: 693-698
122. Van Deuren M, van der Ven-Jongekrijg J, Demacker PNM, Bartelink Akm, van Dalen R, Sauerwein RW, Gallati H, Vannice JL, van der Meer JWM (1994) Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis 169: 157-161
123. Van Deventer SJH, Buller H, ten Cate JW, Sturk A, Pouw W (1988) Endotoxaemia: an early predictor of septicemia in febrile patients. Lancet 1: 605-609
124. Van Deventer SJH, Büller HR, ten Cate JW, Aarden LA, Hack E, Sturk A (1990) Experimental endotoxmemia in humans: analysts of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 76: 2520-2526
125. Van Deventer SJH, Hart M, van der Poll T, Hack CE, Aarden LA (1993) Endotoxin and tumor necrosis factor-α-induced interleukin-8 release in humans. J Infect Dis 167: 461-464
126. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl Acad Sci USA 89: 4845-4849
127. Van Zee KJ, Coyle SM, Calvano SE, Oldenburg HSA, Stiles DM, Pribble J, Catalano M, Moldawer LL, Lowry SF (1995) Influence of IL-1 receptor blockade on the human response to endotoxinemia. J Immunol 154: 1499-1507
128. Waage A, Aasen AO (1992) Different role of cytokin mediators in septic shock related to meningococcal disease and surgery/polytrauma. Immunol Rev 127: 221-230
129. Waage A, Halstensen A, Espevik T (1987) Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1: 355-357
130. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 169: 33-38
131. Waage A, Halstensen A, Espevik T, Brandtzaeg P (1994) Cytokines in meningococcal disease. Baillières Clin Infect Dis 1: 97-108
132. Waring PM, Waring JL, Metcalf D (1994) Circulating leukemia inhibiting factor levels correlate with disease severity in meningococcemia. J Infect Dis 170: 1224-1228
133. Whaley K, Khong TY, McCartney AC, Ledingham IM (1979) Complement activation and its control in gram negative endotoxic shock. J Clin Lab Immunol 2: 117-124
134. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC (1990) CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249: 1431-1433
135. Young LS, Proctor RA, Beutler B, McCabe WR, Sheagren JN (1991) University of California/Davis interdepartmental conference on gram-negative septicemia. Rev Infect Dis 13: 666-687
136. Zabel P, Wolter DT, Schönharting MM, Schade UF (1989) Oxpentifyllin in endotoxaemia. Lancet 2: 1474-1477
137. Zumla A (1992) Superantigens, T cells and microbes. Clin Infect Dis 15: 313-320